Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anxiolytic and anticonvulsant properties. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a more favorable side-effect profile regarding sedation and cognitive impairment.
## Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). Note: Off-label use for refractory epilepsy or acute anxiety is common depending on local clinical protocols.
## Adult Dosing
* **Initial Dose:** 10 mg daily (divided twice daily).
* **Titration:** May increase at weekly intervals.
* **Target/Maintenance Dose:** 20 mg to 40 mg daily, administered in two divided doses. Doses >40 mg/day have not been adequately studied and are not recommended.
## Pediatric Dosing (≥2 years)
Weight-based dosing is required for patients ≤30 kg:
* **Patients ≤30 kg:** Start at 5 mg daily. May increase to 10 mg daily after 1 week, then up to 20 mg daily as tolerated.
* **Patients >30 kg:** Follow adult dosing (start 10 mg/day, titrate to 20–40 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50%; titrate slowly. Use with caution in severe impairment.
* **Renal Impairment:** No specific adjustment required; use with caution.
* **CYP2C19 Poor Metabolizers:** Exposure to the active metabolite (N-desmethylclobazam) is significantly increased. Consider starting at 50% of the recommended dose.
## Contraindications
* Known hypersensitivity to clobazam or any product component.
* Myasthenia gravis (relative).
## Adverse Effects
* **Most Common:** Somnolence, sedation, lethargy, drooling (sialorrhea), constipation, pyrexia, ataxia, and fatigue.
* **Serious:** Severe dermatological reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), suicidal ideation, and respiratory depression.
## Key Drug Interactions
* **CNS Depressants:** Additive sedation; exercise extreme caution with opioids, alcohol, or other benzodiazepines.
* **CYP2C19 Inhibitors:** (e.g., fluconazole, fluvoxamine, omeprazole) Increase clobazam/metabolite levels, potentially increasing toxicity.
* **CYP2C19 Inducers:** (e.g., rifampin, St. John's wort) May decrease serum concentrations.
* **Hormonal Contraceptives:** May decrease efficacy (clobazam is a mild CYP3A4 inducer).
## Monitoring
* **Respiratory Status:** Monitor for signs of shallow breathing or hypoxia, especially in combination with opioids.
* **Mental Health:** Monitor for new or worsening depression, anxiety, or suicidal ideation.
* **Dermatological:** Monitor for rash or mucosal lesions; discontinue immediately if signs of SJS/TEN appear.
## Clinical Pearls
* **Withdrawal:** Do not stop abruptly; taper slowly to prevent seizure rebound or status epilepticus.
* **Tolerance:** Clinical studies suggest tolerance to the anticonvulsant effects may develop over time.
* **Administration:** Tablets can be crushed and mixed with applesauce; the oral suspension should be shaken well before use.
* **Controlled Substance:** Clobazam is a Schedule IV controlled substance.
***
*Disclaimer: This information is for educational purposes only. Always verify dosages, contraindications, and drug interactions against current institutional protocols, prescribing leaflets, or clinical decision support tools before prescribing or administering medication.*
